NellOne Therapeutics
Early-stage biopharmaceutical company developing a recombinant signaling-protein therapeutic platform to promote regeneration of damaged soft and hard tissues and to modulate inflammation. The company advances a proprietary engineered variant of a naturally occurring signaling protein for applications including inflammatory respiratory disease (ARDS/COVID-19), wound healing, cardiac and skeletal muscle repair, and other regenerative indications. Activities reported include preclinical efficacy studies, intellectual property development, licensing of a targeted drug-delivery approach, assay development partnerships, and efforts to scale production for commercial deployment.
Industries
Nr. of Employees
small (1-50)
NellOne Therapeutics
Patents
Products
Recombinant NELL1 variant (NV1)
A proprietary, engineered recombinant variant of a naturally occurring signaling protein intended to modulate inflammation and promote tissue regeneration across multiple organs; reported to have improved efficacy and manufacturing characteristics versus the full-length protein.
NELL1
NELL1 plays a critical role in early bone formation, repair after injury, and degenerative diseases such as osteoporosis. It is a protein used as a potential regenerative therapy platform for bone and cartilage injury and related conditions.
NELL1 protein therapeutic
A therapeutic protein candidate developed by NellOne Therapeutics for treating tissue damage and inflammation resulting from respiratory viral infections including COVID-19, promoting tissue regeneration and immune system balance.
NV1
NV1 is a patented variant of neural epidermal growth factor-like (NELL1) protein being commercialized by NellOne for unmet inflammatory lung health market needs and licensing partnerships. It promotes new tissue formation and maturation by regulating the composition of the extracellular matrix, aiding in healing, balancing hyperinflammation, and promoting regeneration in post-injury tissue damage.
NELL-1
NELL-1 is a therapeutic agent critical for early vasculature and cardiac tissue formation, shown to help overcome cell death in cardiomyocytes under hypoxic conditions and during Acute Myocardial Infarction (AMI).
Recombinant NELL1 variant (NV1)
A proprietary, engineered recombinant variant of a naturally occurring signaling protein intended to modulate inflammation and promote tissue regeneration across multiple organs; reported to have improved efficacy and manufacturing characteristics versus the full-length protein.
NELL1
NELL1 plays a critical role in early bone formation, repair after injury, and degenerative diseases such as osteoporosis. It is a protein used as a potential regenerative therapy platform for bone and cartilage injury and related conditions.
NELL1 protein therapeutic
A therapeutic protein candidate developed by NellOne Therapeutics for treating tissue damage and inflammation resulting from respiratory viral infections including COVID-19, promoting tissue regeneration and immune system balance.
NV1
NV1 is a patented variant of neural epidermal growth factor-like (NELL1) protein being commercialized by NellOne for unmet inflammatory lung health market needs and licensing partnerships. It promotes new tissue formation and maturation by regulating the composition of the extracellular matrix, aiding in healing, balancing hyperinflammation, and promoting regeneration in post-injury tissue damage.
NELL-1
NELL-1 is a therapeutic agent critical for early vasculature and cardiac tissue formation, shown to help overcome cell death in cardiomyocytes under hypoxic conditions and during Acute Myocardial Infarction (AMI).
Services
Partnerships and licensing of laboratory technologies and IP to support development of therapeutic candidates and delivery systems.
Development and optimization of assays and quality-control tests to accelerate candidate evaluation and manufacturing release testing.
Partnerships and licensing of laboratory technologies and IP to support development of therapeutic candidates and delivery systems.
Development and optimization of assays and quality-control tests to accelerate candidate evaluation and manufacturing release testing.
Expertise Areas
- Regenerative medicine
- Recombinant protein therapeutics
- Biologics manufacturing and scale-up
- Preclinical ARDS and respiratory-disease models
Key Technologies
- Recombinant protein engineering
- Nanoparticle / liposome-based targeted delivery
- Ex vivo human lung tissue assays
- Mouse models of viral infection / ARDS
News & Updates
Announcement of plans to open a research and development laboratory at the Fairview Technology Center in Knox County to expand R&D capacity and create jobs.
License of an Oak Ridge National Laboratory technology for nanoparticle (liposome) delivery exploiting a viral spike-protein targeting mechanism to deliver therapeutics to infected cells.
Awarded an NSF Small Business Innovation Research (SBIR) Phase I grant ($250,000) to conduct R&D evaluating a proprietary recombinant variant in cultured human lung tissues and mouse models of SARS-CoV-2 infection.
Announced expansion of a partnership to develop and optimize assays and tests to evaluate the candidate therapeutic in ARDS models.
USPTO issued U.S. Patent No. 10,752,663 covering a novel engineered variant with claims relevant to large-scale production and clinical applications.
Filed a provisional patent application describing methods and compositions for treating tissue damage resulting from viral infections including SARS-CoV-2 (COVID-19).
Announcement of plans to open a research and development laboratory at the Fairview Technology Center in Knox County to expand R&D capacity and create jobs.
License of an Oak Ridge National Laboratory technology for nanoparticle (liposome) delivery exploiting a viral spike-protein targeting mechanism to deliver therapeutics to infected cells.
Awarded an NSF Small Business Innovation Research (SBIR) Phase I grant ($250,000) to conduct R&D evaluating a proprietary recombinant variant in cultured human lung tissues and mouse models of SARS-CoV-2 infection.
Announced expansion of a partnership to develop and optimize assays and tests to evaluate the candidate therapeutic in ARDS models.
USPTO issued U.S. Patent No. 10,752,663 covering a novel engineered variant with claims relevant to large-scale production and clinical applications.
Filed a provisional patent application describing methods and compositions for treating tissue damage resulting from viral infections including SARS-CoV-2 (COVID-19).